BioCryst signs agreement with Er-Kim Pharmaceuticals to commercialise ORLADEYO in Turkey
ORLADEYO (berotralstat) is claimed to be the first and only oral treatment intended particularly to prevent attacks of hereditary angioedema (HAE) in adult and paediatric patients aged 12 years
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.